Stock Detail
UNITED THERAPEUTICS CORPORATION
Sector: Drug Manufacturers Other
Latest Quote @ Wed May 5 20:19:29 (15 min delayed)
| N/A |
N/A |
$67.82 |
-0.65 |
-0.95% |
|
Last Day's Data
| $68.47 |
$68.86 |
$0.36 |
0.53% |
0.00 |
$68.11 |
| $68.38 |
$67.38 |
801,263.00 |
3.40B |
774,776.00 |
12.17 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 69.72 |
69.10 |
68.24 |
67.62 |
66.76 |
Stock Profile
United Therapeutics Corporation (UTC), a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular, cancer, and infectious diseases. The company's primary product, Remodulin, an injection for the treatment of pulmonary arterial hypertension in patients with NYHA class II-IV symptoms to diminish symptoms associated with exercise. UTC also develops four therapeutic platforms: immunotherapeutic monoclonal antibodies, which are antibodies that activate patients' immune systems to treat cancer, including OvaRex, which would be used for the treatment of metastatic ovarian cancer; glycobiology antiviral agents that are small molecules and would be used as an oral therapy for hepatitis C and other infections; telemedicine, which includes sportable digital devices that enable physicians to remotely monitor patients' bodily measurements such as heart function, including the CardioPAL family of cardiac event recorders and the Decipher Holter monitors; and arginine formulations, including the HeartBar and other products, which deliver the amino acid arginine that is necessary for maintaining vascular function. The company was founded in 1996 as Lung Rx, Inc. and changed its name to United Therapeutics Corporation in 1997. UTC was founded by Martine Rothblatt. United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
